Back to BAKER BROS. ADVISORS LP BAKER BROS. ADVISORS LP

DNLIDNLI
Showing 8 of 26 quarters

Position history for BAKER BROS. ADVISORS LPBAKER BROS. ADVISORS LP's holdings in DENALI THERAPEUTICS INC

Yes. Baker Bros. Advisors holds 3,734,336 shares of DNLI (Denali Therapeutics), worth $96M, as of its Q2 2026 13F filing. It increased the position by 2,641 shares (+0.1%) from Q1 2026. Baker Bros. Advisors has held DNLI since Q1 2020, across 26 quarterly 13F filings. DNLI is 0.5% of Baker Bros. Advisors' reported 13F portfolio.

Current Value

$96M

Current Shares

3.7M

Total Value Change

-$12.7M

Total Shares Change

+2,641

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
3.7M
+0.1%
$96M0.5%$25.72
36
2026-Q1
Unchanged
3.7M
0.0%
$71.6M0.4%$20.02
0
2025-Q4
Unchanged
3.7M
0.0%
$61.6M0.4%$16.41
0
2025-Q3
Unchanged
3.7M
0.0%
$54.2M0.4%$14.52
0
2025-Q2
Unchanged
3.7M
0.0%
$52.2M0.5%$14.10
0
2025-Q1
Unchanged
3.7M
0.0%
$50.7M0.6%$14.78
0
2024-Q4
Unchanged
3.7M
0.0%
$76.1M0.8%$20.24
0
2024-Q3
Unchanged
3.7M
0.0%
$108.7M1.1%$29.43
0

Other major holders of DNLI: BAILLIE GIFFORD & CO

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used